



Made
for us

STADA
Specialty Care

UZPRUVO[®] STADA's ustekinumab biosimilar is now available

Prescribing Information can be found [here](#)

Uzpruvo[®] (ustekinumab) offers a cost-effective alternative to the reference product^{1,2}

As part of STADA's commitment to caring for people's health and supporting the NHS in its mission to provide high quality healthcare to all patients across the UK, we have now entered the global biosimilar pipeline for immunology.

STADA UK's product Uzpruvo[®] is available and is indicated for the treatment of:



Plaque psoriasis²

Adults with moderate to severe plaque psoriasis who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate (MTX) or psoralen and ultraviolet A (PUVA).²



Paediatric plaque psoriasis²

Uzpruvo[®] is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescent patients from the age of 6 years and older, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.²



Psoriatic arthritis²

Adult patients with active psoriatic arthritis, alone or in combination with MTX, when the response to previous non-biological disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate.²



Crohn's disease²

Adult patients with moderately to severely active Crohn's disease who have had an inadequate response with, or lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor.²

Uzpruvo[®] has received marketing authorisation for equivalent indications to Stelara[®] with the exception of ulcerative colitis (since the originator still has exclusivity for this indication).²

Why choose Uzpruvo[®]



Cost-effective option enabling improved access to ustekinumab treatment^{1,2}




Patient-friendly pre-filled syringe: easy handling, thinner needle than reference product & latex-free^{3,2,3,4}



Equivalent efficacy, safety and immunogenicity to the reference product^{1,5}



Three Homecare partners; Sciensus, HealthNet and LPCH offering flexible delivery and nurse support for your patients



Patient support is available and patients can manage their own deliveries with the flexibility to reschedule

Healthcare Professional support from a dedicated Homecare Account Manager within STADA UK, Thornton and Ross, to help and support with any Homecare queries homecare@thorntonross.com

STADA UK – Caring for People's Health as a Trusted Partner



+15 years' experience and 6 biosimilars in the global market, with a continuously expanding portfolio⁶



Supply chain excellence with supply service levels exceeding 95% throughout 2022⁷

Adverse events should be reported to Thornton and Ross Limited by emailing thorntonross@medinformation.co.uk or by calling 01484 848164. Additionally, reporting forms and information can be found at: <https://yellowcard.mhra.gov.uk> or search for MHRA Yellow Card in the Google Play or Apple App Store.

PFS, pre-filled syringe. ¥ Plunger stopper made of bromobutyl rubber. † Stelara[®];

* Supply chain is constantly being optimised and manufacturing location is subject to change.

1. Cost of Uzpruvo[®] (ustekinumab) and reference product taken from NHS DM+D. Available at: <https://dmd-browser.nhsbsa.nhs.uk> Accessed July 2024. 2. Uzpruvo[®] (ustekinumab) SmPC. Available at <https://www.medicines.org.uk/emc/search?q=Uzpruvo> Last accessed: June 2024. 3. Stelara package insert. Available at: <https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf>. Accessed June 2024. 4. Jaber A, Bozzato GB, Vedrine L, Prais WA, Berube J, Laurent PE. A novel needle for subcutaneous injection of interferon beta-1a: effect on pain in volunteers and satisfaction in patients with multiple sclerosis. BMC Neurol. 2008 Oct 10;8:38. doi: 10.1186/1471-2377-8-38. PMID: 18845005; PMCID: PMC2577094. Available at: <https://pubmed.ncbi.nlm.nih.gov/18845005/>. Last accessed: June 2024. 5. Feldman SR et al. Expert Opin Biol Ther. 2023;23(3):253-60. DOI:10.1080/14712598.2023.2235263. 6. Biosimilars_corporate_brochure.pdf (https://rxdetail.co.uk/biosimilars/Biosimilars_corporate_brochure.pdf). 7. STADA | Press Release 06/03/2023. Available at: <https://www.stada.com/blog/posts/2023/march/stada-sustains-strong-momentum-with-double-digit-sales-and-profit-growth-in-2022>. Last accessed: June 2024.